A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE)
Latest Information Update: 17 Apr 2025
At a glance
- Drugs Benralizumab (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms RESOLUTE
- Sponsors AstraZeneca; AstraZeneca AB; AstraZeneca KK
Most Recent Events
- 14 Apr 2025 Planned End Date changed from 21 Aug 2025 to 8 Aug 2025.
- 14 Apr 2025 Planned primary completion date changed from 21 Aug 2025 to 8 Aug 2025.
- 07 May 2024 Planned End Date changed from 27 Jun 2025 to 21 Aug 2025.